JP2018525320A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525320A5
JP2018525320A5 JP2017558673A JP2017558673A JP2018525320A5 JP 2018525320 A5 JP2018525320 A5 JP 2018525320A5 JP 2017558673 A JP2017558673 A JP 2017558673A JP 2017558673 A JP2017558673 A JP 2017558673A JP 2018525320 A5 JP2018525320 A5 JP 2018525320A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
amino acid
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017558673A
Other languages
English (en)
Japanese (ja)
Other versions
JP6857138B2 (ja
JP2018525320A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/033153 external-priority patent/WO2016187354A1/en
Publication of JP2018525320A publication Critical patent/JP2018525320A/ja
Publication of JP2018525320A5 publication Critical patent/JP2018525320A5/ja
Application granted granted Critical
Publication of JP6857138B2 publication Critical patent/JP6857138B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017558673A 2015-05-18 2016-05-18 Axlタンパク質に結合する抗体 Active JP6857138B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163264P 2015-05-18 2015-05-18
US62/163,264 2015-05-18
PCT/US2016/033153 WO2016187354A1 (en) 2015-05-18 2016-05-18 Antibodies that bind to axl proteins

Publications (3)

Publication Number Publication Date
JP2018525320A JP2018525320A (ja) 2018-09-06
JP2018525320A5 true JP2018525320A5 (enExample) 2019-06-20
JP6857138B2 JP6857138B2 (ja) 2021-04-14

Family

ID=57320780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017558673A Active JP6857138B2 (ja) 2015-05-18 2016-05-18 Axlタンパク質に結合する抗体

Country Status (4)

Country Link
US (3) US10787516B2 (enExample)
EP (1) EP3297662A4 (enExample)
JP (1) JP6857138B2 (enExample)
WO (1) WO2016187354A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
ES3063952T3 (en) 2015-05-18 2026-04-21 Agensys Inc Antibodies that bind to axl proteins
KR101909955B1 (ko) * 2016-11-28 2018-10-19 재단법인 목암생명과학연구소 신규 항-에이엑스엘 항체 및 이를 포함하는 약학적 조성물
KR20200067145A (ko) 2017-09-13 2020-06-11 내셔날 리서치 카운실 오브 캐나다 Axl-특이적 항체 및 그의 용도
CN110483639A (zh) 2018-05-15 2019-11-22 复旦大学 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
CN113045664B (zh) * 2019-11-28 2023-05-12 尚健单抗(北京)生物技术有限公司 一种分离的结合抗原axl的蛋白及其用途
WO2022197699A1 (en) * 2021-03-17 2022-09-22 Eli Lilly And Company Human tspan33 antibodies
US20250154237A1 (en) * 2022-02-24 2025-05-15 A & G Pharmaceutical, Inc. Fully human monoclonal antibodies against human progranulin

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
KR100845354B1 (ko) 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항-ctla-4 항체의 용도
CA2575791A1 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
BRPI0820073A2 (pt) * 2007-11-12 2015-06-23 U3 Pharma Gmbh Anticorpos anti-axl
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP2012521197A (ja) * 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
AR076564A1 (es) * 2009-05-11 2011-06-22 U3 Pharma Gmbh Anticuerpos humanizados de axl(receptor de tirosina quinasa)
PH12012500564A1 (en) 2009-10-09 2012-10-22 Sanofi Sa Polypeptides for binding to the receptor for advanced glycation endproducts as well as compositions and methods involving the same
CN103080136B (zh) * 2010-06-18 2015-08-12 霍夫曼-拉罗奇有限公司 抗Axl抗体及使用方法
AU2012273955A1 (en) * 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
WO2012175691A1 (en) 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
BR102013027577A2 (pt) 2012-10-25 2016-03-29 Memorialsloan Kettering Cancer Ct método de detecção de um nível aumentado de axl ou gas6 e método de identificação de um paciente com câncer resistente a inibidor de egfr
KR102167228B1 (ko) 2012-11-05 2020-10-19 피에르 파브르 메디카먼트 새로운 항원 결합 단백질들 및 암의 치료를 위한 어드레싱 산물로서 그들의 용도
WO2016187354A1 (en) * 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
ES3063952T3 (en) 2015-05-18 2026-04-21 Agensys Inc Antibodies that bind to axl proteins
CN107074943B (zh) * 2016-07-14 2018-08-24 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
JP2023517234A (ja) * 2020-03-09 2023-04-24 アブセレラ バイオロジクス インコーポレイテッド 抗コロナウイルス抗体および使用の方法
EP4277926A1 (en) * 2021-01-15 2023-11-22 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies

Similar Documents

Publication Publication Date Title
JP2020522261A5 (enExample)
JP2022521551A5 (enExample)
JP2020526478A5 (enExample)
JP2018516853A5 (enExample)
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
JP2019527553A5 (enExample)
RU2018108048A (ru) Новые анти-pd-1 антитела
JP2010536384A5 (enExample)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
PE20221511A1 (es) Anticuerpos anti-ly6g6d y metodos de uso
NZ601858A (en) Methods and compositions for diagnosis and treatment of amyloidosis
JP2016527225A5 (enExample)
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
JP2018512379A5 (enExample)
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
JP2020533016A5 (enExample)
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
JP2013500940A5 (enExample)
JP2013515013A5 (enExample)
JP2021517152A5 (enExample)
RU2011121818A (ru) Способ иммунологического анализа белка cxcl1 человека
JP2017521054A5 (enExample)
JP2017524362A5 (enExample)
JP2016501877A5 (enExample)
JP2023518225A5 (enExample)